Episurf Medical Q4: First steps for the US market

Research Update

2023-02-20

07:30

Redeye notes a continuous customer base growth (+72%), and we are encouraged by the company’s FDA approval for its Episealer Patellofemoral System, marking its first steps on US soil. Sales were in line with our estimates, albeit still at low figures. OPEX came in 19% higher, though without any reason for concern going forward.

OB

Oscar Bergman

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.